MAP2K7 and renal cell carcinoma: Diaz-Montero et al. [136] investigated treatment with sunitinib (a member of VEGF TKI class) and a MEK inhibitor in renal cell carcinoma (RCC) patient-derived xenograft (PDX) mouse models, concluding that decreasing the level of G-CSF and the accumulation of G-MDSCs, significantly delaying drug resistance.